---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-24-000016"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T08:59:52.705954+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Keros Therapeutics reports Q4 2023 net loss of $40.2M, cash $331.1M; extends runway into 2027

## Summary
- Net loss of $40.2M in Q4 2023 ($153.0M for FY) vs $29.7M and $104.7M in prior year periods.
- Revenue of $0.2M in 2023 from license agreement with Hansoh; no revenue in 2022.
- R&D expenses rose to $37.5M in Q4 (FY $135.3M) driven by Phase 2 trials of KER-050 and KER-012.
- Cash and equivalents $331.1M at Dec 31, 2023; January 2024 public offering of 4.025M shares at $40/sh adds net proceeds, funding into 2027.
- Anticipated milestones: Phase 3 trial design for KER-050 in MDS in H1 2024; data readouts throughout 2024.

## SEC filing metadata
- accession: 0001664710-24-000016
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000016/0001664710-24-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000016/kros-20240228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-24-000016
- JSON: https://secwatch.observer/filing/0001664710-24-000016.json
- Plain text: https://secwatch.observer/filing/0001664710-24-000016.txt

## Key facts
- Earnings Releases
  Keros Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $0.2 million for the year ended December 31, 2023, net income a net loss of $40.2 million for the fourth quarter and $153.0 million for the year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Revenue: $0.2 million for the year ended December 31, 2023
  - Net income: a net loss of $40.2 million for the fourth quarter and $153.0 million for the year ended December 31, 2023
  - Result: reported results
  source text: Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000016/0001664710-24-000016-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.